Please assess the completion status of the following clinical trial:

Trial Title: Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is scheduled to undergo primary unilateral TKA under spinal anesthesia.~* Has not previously undergone TKA in either knee.~* Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.~* Is able to walk at least 20 feet with optional use of a 4-legged walker for balance.~* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or is at least 2 years post-menopausal; or is in a monogamous relationship with a partner who is surgically sterile; or using acceptable contraceptives.~Exclusion Criteria:~* Has a planned concurrent surgical procedure.~* Has other pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.~* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.~* Using or expected to use Factor IX Complex or anti-inhibitor coagulant concentrates during the study.~* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.~* Has taken NSAIDs within 10 days prior to the scheduled surgery with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.~* Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).~* Has been administered bupivacaine within 5 days prior to the scheduled surgery.~* Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.~* Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.~* Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.~* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.~* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.~* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.~* Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.~* Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.~* Has acquired defective color vision or acute gastrointestinal ulcers, either of which could interfere with scheduled study medications.~* Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature.~* Has any chronic condition or disease that would compromise neurological or vascular assessments.~* Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.~* Has undergone 3 or more surgeries within 12 months.~* Has a body mass index (BMI) \>39 kg/m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): HTX-011 + MMA
- Cohort 2 (Type: EXPERIMENTAL): HTX-011 + MMA
- Cohort 3 (Type: EXPERIMENTAL): HTX-011 + MMA
- Cohort 4 (Type: EXPERIMENTAL): HTX-011 + MMA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete